Welcome to our dedicated page for Kezar Life Sciences SEC filings (Ticker: KZR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kezar Life Sciences, Inc. filings document a clinical-stage biotechnology issuer through material-event reports, capital-structure disclosures, governance matters and corporate-status records. The company’s 8-K filings cover zetomipzomib program updates, operating and financial results, amendments affecting preferred share purchase rights, repayment and termination of a loan agreement, and restructuring costs associated with exit activities.
The filing record also documents completed transaction and status events, including the asset purchase agreement transferring Kezar’s Sec61-based discovery and development program assets, including KZR-261, to Enodia Therapeutics, tender-offer consideration involving cash and contingent value rights, and Nasdaq’s Form 25 notice for removal of Kezar common stock from listing and registration.
Form 4 Filing Details: Micki Klearman, Director at Kezar Life Sciences (KZR), received a stock option grant on June 18, 2025. The transaction involves the acquisition of 5,000 stock options with the following key terms:
- Exercise price set at $4.46 per share
- Options expire on June 17, 2035
- 100% vesting scheduled for June 18, 2026, contingent on continued service
- Underlying security is Common Stock
This Form 4 filing, signed by Marc Belsky as Attorney-in-Fact on June 23, 2025, represents a standard director compensation equity grant. The options provide Klearman with the right to purchase 5,000 shares of Kezar Life Sciences common stock upon vesting, aligning the director's interests with those of shareholders through long-term equity ownership potential.
Kezar Life Sciences Director Michael Kauffman received a stock option grant on June 18, 2025, according to a Form 4 filing. The derivative security details include:
- Grant of 5,000 stock options to purchase common stock
- Exercise price set at $4.46 per share
- Options will vest 100% on June 18, 2026, subject to continued service
- Options expire on June 17, 2035
The transaction represents a standard director compensation grant. Kauffman holds the options directly, with no indirect beneficial ownership reported. The filing was signed by Marc Belsky as attorney-in-fact on June 23, 2025.
Director Courtney Wallace of Kezar Life Sciences received a stock option grant on June 18, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:
- Granted 5,000 stock options to purchase common stock
- Exercise price set at $4.46 per share
- 100% vesting scheduled for June 18, 2026, contingent on continued service
- Options expire on June 17, 2035
This grant represents standard director compensation and aligns the director's interests with shareholders through long-term equity incentives. The Form 4 was filed within the required reporting timeline, signed by Marc Belsky as attorney-in-fact on June 23, 2025.
Elizabeth Garner, Director at Kezar Life Sciences (KZR), received a stock option grant on June 18, 2025. The derivative securities transaction details include:
- Granted 5,000 stock options to purchase common stock
- Exercise price set at $4.46 per share
- Options will vest 100% on June 18, 2026, subject to continued service
- Options expire on June 17, 2035
This Form 4 filing represents a standard director compensation equity grant. The options provide Garner with the right to purchase company shares at a fixed price, aligning her interests with shareholders over the long term. The one-year cliff vesting schedule incentivizes retention and continued service on the board.
Director Graham K. Cooper of Kezar Life Sciences received a stock option grant on June 18, 2025, as reported in this Form 4 filing. The transaction details include:
- Granted 5,000 stock options to purchase common stock
- Exercise price set at $4.46 per share
- Options will vest 100% on June 18, 2026, subject to continued service
- Options expire on June 17, 2035
This grant represents standard director compensation and was filed within the required reporting timeframe. The options provide Cooper with the right to purchase Kezar shares at a fixed price over the next decade, aligning his interests with shareholders' long-term value creation.
The Form 4 filing dated 06/23/2025 discloses that Kezar Life Sciences (KZR) director Franklin M. Berger received a new equity incentive on 06/18/2025.
- Instrument: Non-qualified stock option covering 5,000 common shares.
- Exercise price: $4.46 per share.
- Vesting: 100 % cliff vest on 06/18/2026, contingent upon continued service.
- Expiration: 06/17/2035 (10-year term).
- Post-grant holdings: 5,000 derivative securities, held directly.
No non-derivative share transactions were reported and no shares were sold. The filing represents a routine incentive grant, typical for board members, and does not signal a change in ownership control or near-term liquidity activity.
Kezar Life Sciences director John Franklin Fowler received a stock option grant on June 18, 2025. The key details of this insider transaction include:
- Granted 5,000 stock options to purchase common stock
- Exercise price set at $4.46 per share
- Options will vest 100% on June 18, 2026, subject to continued service
- Options expire on June 17, 2035
This Form 4 filing represents a standard director compensation grant. The vesting schedule indicates a one-year cliff vesting period, which aligns with typical board member equity compensation structures. The 10-year exercise window from grant date is also standard practice for director stock options.
Kezar Life Sciences (Nasdaq: KZR) filed a Form 8-K disclosing the voting results of its 17 June 2025 annual meeting (Item 5.07).
Shareholders elected three Class I directors to serve until the 2028 meeting: Elizabeth Garner, M.D. (2,148,505 for / 1,793,162 withheld), Michael Kauffman, M.D., Ph.D. (1,618,735 for / 2,322,932 withheld) and Courtney Wallace (1,551,353 for / 2,390,314 withheld).
The meeting also approved, on an advisory basis, executive compensation (2,151,745 for; 1,781,942 against; 7,980 abstain) and ratified KPMG LLP as independent auditor for fiscal 2025 (6,116,820 for; 56,801 against; 8,526 abstain).
No financial performance updates, strategic announcements or other material events were included.